Sreeparna Vappala

Sreeparna Vappala

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2017 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
SASrinivas Abbina
Srinivas Abbina
SVSreeparna Vappala
Sreeparna Vappala
PKPrashant Kumar
Prashant Kumar
ESErika M. J. Siren
Erika M. J. Siren
CLChanel C. La
Chanel C. La
JKJayachandran N. Kizhakkedathu
Jayachandran N. Kizhakkedathu
In the pursuit of dendrimer alternatives, hyperbranched polymers have found increasing interest from academia and industry in a broad range of fields due to their topological and synthetic advantages. Hyperbranched polyglycerol (HPG), as the name implies, is a hyperbranched polymer with about 50–65% dendrimeric structure. Due to its ease in synthesis, globular nature, versatility in terms of functionalization, and superb biocompatibility profiles HPG provides a promising class of materials suitable for numerous applications in nanomedicine and biomedical technologies. The structural features of HPG can be easily tailored by adopting different synthetic methodologies. In this review, we briefly explore the synthesis of HPGs starting from the traditional Lewis acid based approaches to recent advances including the development of high MW HPGs, biodegradable HPGs, co-block HPGs and sustainable or ‘green’ HPG synthesis. The robust history of HPG biocompatibility is extensively reviewed giving examples of both in vitro and in vivo models. In particular, HPG showed very minimal polymer accumulation in vital organs after intravenous injection compared to other polymers widely used for various biomedical applications. HPG is well tolerated in mice and rats, and has been found to be non-immunogenic to date. Due to its demonstrated safety profile and multifunctionality, HPG has been extensively studied for different biomedical applications including as macromolecular therapeutics, multivalent inhibitors/scavengers, in controlled drug delivery systems, in organ preservation, dialysis and cell surface engineering, as imaging agents and theranostics, in the development of anti-fouling surfaces and proteomics reagents. We highlight these applications along with its advantages. Finally, we conclude by providing a future prospective of HPG as one of the promising PEG alternatives with a great potential to enter clinical trials in the near future.

26 April 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
CLChanel C. La
Chanel C. La
SSStephanie A. Smith
Stephanie A. Smith
SVSreeparna Vappala
Sreeparna Vappala
RAReheman Adili
Reheman Adili
CLCatherine E. Luke
Catherine E. Luke
JKJayachandran N. Kizhakkedathu
Jayachandran N. Kizhakkedathu
Current treatments to prevent thrombosis, namely anticoagulants and platelets antagonists, remain complicated by the persistent risk of bleeding. Improved therapeutic strategies that diminish this risk would have a huge clinical impact. Antithrombotic agents that neutralize and inhibit polyphosphate (polyP) can be a powerful approach towards such a goal. Here, we report a design concept towards polyP inhibition, termed macromolecular polyanion inhibitors (MPI), with high binding affinity and specificity. Lead antithrombotic candidates are identified through a library screening of molecules which possess low charge density at physiological pH but which increase their charge upon binding to polyP, providing a smart way to enhance their activity and selectivity. The lead MPI candidates demonstrates antithrombotic activity in mouse models of thrombosis, does not give rise to bleeding, and is well tolerated in mice even at very high doses. The developed inhibitor is anticipated to open avenues in thrombosis prevention without bleeding risk, a challenge not addressed by current therapies.

1 May 2019 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MSManmeet Singh
Manmeet Singh
AKAbhinoy Kishore
Abhinoy Kishore
Dibyajyoti MaityDibyajyoti Maity
Dibyajyoti Maity
SPSunanda Punnepalli
Sunanda Punnepalli
BKBankala Krishnarjuna
Bankala Krishnarjuna
JSJayasri Das Sarma
Jayasri Das Sarma
Fusion peptides (FPs) in spike proteins are key players mediating early events in cell-to-cell fusion, vital for intercellular viral spread. A proline residue located at the central FP region has often been suggested to have a distinctive role in this fusion event. The spike glycoprotein from strain RSA59 (PP) of mouse hepatitis virus (MHV) contains two central, consecutive prolines in the FP. Here, we report that deletion of one of these proline residues, resulting in RSA59 (P), significantly affected neural cell syncytia formation and viral titers postinfection in vitro. Transcranial inoculation of C57Bl/6 mice with RSA59 (PP) or RSA59 (P) yielded similar degrees of necrotizing hepatitis and meningitis, but only RSA59 (PP) produced widespread encephalitis that extended deeply into the brain parenchyma. By day 6 postinfection, both virus variants were mostly cleared from the brain. Interestingly, inoculation with the RSA59 (P)–carrying MHV significantly reduced demyelination at the chronic stage. We also found that the presence of two consecutive prolines in FP promotes a more ordered, compact, and rigid structure in the spike protein. These effects on FP structure were due to proline's unique stereochemical properties intrinsic to its secondary amino acid structure, revealed by molecular dynamics and NMR experiments. We therefore propose that the differences in the severity of encephalitis and demyelination between RSA59 (PP) and RSA59 (P) arise from the presence or absence, respectively, of the two consecutive prolines in FP. Our studies define a structural determinant of MHV entry in the brain parenchyma important for altered neuropathogenesis.

4 June 2020 in Biomacromolecules
Verified
Journal Article
Closed access
CLChanel C. La
Chanel C. La
LTLily E. Takeuchi
Lily E. Takeuchi
SASrinivas Abbina
Srinivas Abbina
SVSreeparna Vappala
Sreeparna Vappala
UAUsama Abbasi
Usama Abbasi
JKJayachandran N. Kizhakkedathu
Jayachandran N. Kizhakkedathu

1 December 2021 in Journal of the Mechanical Behavior of Biomedical Materials
Verified
Journal Article
Closed access
HYHan Hung Yeh
Han Hung Yeh
KYKai Yu
Kai Yu
SVSreeparna Vappala
Sreeparna Vappala
MKManu Thomas Kalathottukaren
Manu Thomas Kalathottukaren
SASrinivas Abbina
Srinivas Abbina
JKJayachandran N. Kizhakkedathu
Jayachandran N. Kizhakkedathu

2 May 2022 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
SASrinivas Abbina
Srinivas Abbina
CLChanel C. La
Chanel C. La
SVSreeparna Vappala
Sreeparna Vappala
MKManu Thomas Kalathottukaren
Manu Thomas Kalathottukaren
UAUsama Abbasi
Usama Abbasi
JKJayachandran N. Kizhakkedathu
Jayachandran N. Kizhakkedathu